Shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) reached a new 52-week high on Tuesday . The stock traded as high as $8.40 and last traded at $7.90, with a volume of 408300 shares trading hands. The stock had previously closed at $7.65.

Several analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of Vascular Biogenics in a research note on Tuesday, November 7th. ValuEngine upgraded shares of Vascular Biogenics from a “sell” rating to a “hold” rating in a research note on Thursday, August 17th. Zacks Investment Research lowered shares of Vascular Biogenics from a “hold” rating to a “sell” rating in a research note on Friday, August 18th. Finally, Chardan Capital boosted their target price on shares of Vascular Biogenics from $20.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, November 6th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $16.00.

Vascular Biogenics (NASDAQ:VBLT) last announced its quarterly earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.01. equities analysts anticipate that Vascular Biogenics Ltd. will post -0.81 earnings per share for the current year.

A hedge fund recently bought a new stake in Vascular Biogenics stock. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 22,100 shares of the biopharmaceutical company’s stock, valued at approximately $135,000. Zurcher Kantonalbank Zurich Cantonalbank owned 0.08% of Vascular Biogenics as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 8.99% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.watchlistnews.com/vascular-biogenics-ltd-vblt-hits-new-52-week-high-at-8-40/1703065.html.

About Vascular Biogenics

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Receive News & Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.